MA35432B1 - Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial - Google Patents
Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytialInfo
- Publication number
- MA35432B1 MA35432B1 MA36815A MA36815A MA35432B1 MA 35432 B1 MA35432 B1 MA 35432B1 MA 36815 A MA36815 A MA 36815A MA 36815 A MA36815 A MA 36815A MA 35432 B1 MA35432 B1 MA 35432B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- prophylaxis
- treatment
- respiratory syncytial
- syncytial virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
L'invention concerne un composé de formule (i), ainsi qu'un sel pharmaceutiquement acceptable de celui-ci, où r
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011078258 | 2011-08-11 | ||
CN2012078439 | 2012-07-10 | ||
PCT/EP2012/065499 WO2013020993A1 (fr) | 2011-08-11 | 2012-08-08 | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35432B1 true MA35432B1 (fr) | 2014-09-01 |
Family
ID=46651492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36815A MA35432B1 (fr) | 2011-08-11 | 2014-03-11 | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial |
Country Status (21)
Country | Link |
---|---|
US (2) | US8871756B2 (fr) |
EP (1) | EP2742039B1 (fr) |
JP (1) | JP5746793B2 (fr) |
KR (1) | KR101570627B1 (fr) |
CN (1) | CN103717589B (fr) |
AU (1) | AU2012293644B2 (fr) |
BR (1) | BR112014003198B1 (fr) |
CA (1) | CA2842123C (fr) |
CL (1) | CL2014000311A1 (fr) |
CO (1) | CO6852080A2 (fr) |
CR (1) | CR20140026A (fr) |
EA (1) | EA023262B1 (fr) |
EC (1) | ECSP14013199A (fr) |
ES (1) | ES2552016T3 (fr) |
HK (1) | HK1196131A1 (fr) |
IL (1) | IL230458A (fr) |
MA (1) | MA35432B1 (fr) |
MX (1) | MX349881B (fr) |
MY (1) | MY184306A (fr) |
PE (1) | PE20142148A1 (fr) |
WO (1) | WO2013020993A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR099134A1 (es) * | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
US9266835B2 (en) * | 2014-02-27 | 2016-02-23 | Janssen Pharmaceutica Nv | Quinoline derivatives useful as CB-1 inverse agonists |
WO2015130445A1 (fr) * | 2014-02-27 | 2015-09-03 | Janssen Pharmaceutica Nv | Dérivés de quinoléine utiles à titre d'agonistes inverses de cb-1 |
CN105726488B (zh) * | 2014-12-08 | 2020-10-20 | 上海爱科百发生物医药技术有限公司 | 含有呼吸道合胞病毒抑制剂的肠溶微丸及其制备方法 |
CN104529802A (zh) * | 2014-12-13 | 2015-04-22 | 西安近代化学研究所 | 一种合成n,n′-双取代氟代丙二酰胺化合物的方法 |
CN104860954B (zh) * | 2015-04-20 | 2018-05-04 | 南京天印健华医药科技有限公司 | 一种苯酯螺吡咯烷类化合物及其制备方法 |
WO2016184832A1 (fr) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Composés pour le traitement d'une amyotrophie spinale |
CN108290882B (zh) * | 2015-07-16 | 2021-07-06 | 豪夫迈·罗氏有限公司 | 用于治疗呼吸道合胞病毒感染的4-喹唑啉胺衍生物的晶形 |
MX2018005890A (es) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Composiciones para tratar atrofia muscular espinal. |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
WO2018013676A1 (fr) | 2016-07-14 | 2018-01-18 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et leurs utilisations |
EA201992878A1 (ru) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни хантингтона |
MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
EP3814360A1 (fr) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Composés hétéroaryles pour le traitement de la maladie de huntington |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
CN113194983A (zh) | 2018-09-06 | 2021-07-30 | 奇达拉治疗公司 | 用于治疗病毒感染的组合物及方法 |
EP3919484B1 (fr) * | 2019-01-29 | 2023-05-24 | Shandong Xuanzhu Pharma Co., Ltd. | Inhibiteur de glycokinase hexanone et son utilisation |
JP2022547538A (ja) * | 2019-09-09 | 2022-11-14 | シダラ セラピューティクス インコーポレーテッド | 呼吸器合胞体ウイルス感染症の処置のための組成物及び方法 |
GB201915273D0 (en) * | 2019-10-22 | 2019-12-04 | Reviral Ltd | Pharmaceutical compounds |
WO2021083290A1 (fr) * | 2019-10-31 | 2021-05-06 | Shanghai Ark Biopharmaceutical Co. Ltd. | Compositions d'inhibiteur de protéine de fusion du virus respiratoire syncytial et méthodes pour le traitement et la prophylaxie de maladies rsv les utilisant |
GB201915932D0 (en) * | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
CN113149977A (zh) | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
EP4210700A1 (fr) | 2020-09-09 | 2023-07-19 | Crinetics Pharmaceuticals, Inc. | Formulations d'un modulateur de somatostatine |
CN113234085A (zh) * | 2021-04-26 | 2021-08-10 | 无锡合全药业有限公司 | 一种2-氧杂-6-氮杂螺[3.4]辛烷-8-基氨基甲酸叔丁酯的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US5874438A (en) * | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
AU2004305039A1 (en) * | 2003-12-12 | 2005-07-07 | Qtl Biosystems Llc | Metal ion mediated fluorescence superquenching assays, kits and reagents |
KR20060127909A (ko) | 2003-12-24 | 2006-12-13 | 비오타 사이언티픽 매니지먼트 피티와이 엘티디 | 호흡기 다핵체 바이러스 감염 치료용 다환 물질 |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
-
2012
- 2012-07-30 US US13/561,366 patent/US8871756B2/en not_active Ceased
- 2012-08-08 EA EA201490419A patent/EA023262B1/ru not_active IP Right Cessation
- 2012-08-08 AU AU2012293644A patent/AU2012293644B2/en active Active
- 2012-08-08 CN CN201280039193.0A patent/CN103717589B/zh active Active
- 2012-08-08 BR BR112014003198-3A patent/BR112014003198B1/pt active IP Right Grant
- 2012-08-08 PE PE2014000187A patent/PE20142148A1/es active IP Right Grant
- 2012-08-08 CA CA2842123A patent/CA2842123C/fr active Active
- 2012-08-08 ES ES12746320.6T patent/ES2552016T3/es active Active
- 2012-08-08 MY MYPI2014700267A patent/MY184306A/en unknown
- 2012-08-08 MX MX2014001481A patent/MX349881B/es active IP Right Grant
- 2012-08-08 JP JP2014524370A patent/JP5746793B2/ja active Active
- 2012-08-08 KR KR1020147006355A patent/KR101570627B1/ko active IP Right Grant
- 2012-08-08 WO PCT/EP2012/065499 patent/WO2013020993A1/fr active Application Filing
- 2012-08-08 EP EP12746320.6A patent/EP2742039B1/fr active Active
-
2014
- 2014-01-14 IL IL230458A patent/IL230458A/en active IP Right Grant
- 2014-01-17 CO CO14008865A patent/CO6852080A2/es active IP Right Grant
- 2014-01-20 CR CR20140026A patent/CR20140026A/es unknown
- 2014-02-07 CL CL2014000311A patent/CL2014000311A1/es unknown
- 2014-02-11 EC ECSP14013199 patent/ECSP14013199A/es unknown
- 2014-03-11 MA MA36815A patent/MA35432B1/fr unknown
- 2014-09-23 HK HK14109553.4A patent/HK1196131A1/zh unknown
-
2020
- 2020-10-21 US US17/075,948 patent/USRE49481E1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2742039B1 (fr) | 2015-09-16 |
EP2742039A1 (fr) | 2014-06-18 |
JP5746793B2 (ja) | 2015-07-08 |
BR112014003198A2 (pt) | 2017-04-04 |
CA2842123C (fr) | 2020-10-06 |
MY184306A (en) | 2021-03-31 |
BR112014003198B1 (pt) | 2020-10-13 |
MX2014001481A (es) | 2014-04-30 |
AU2012293644B2 (en) | 2017-05-25 |
US8871756B2 (en) | 2014-10-28 |
CA2842123A1 (fr) | 2013-02-14 |
IL230458A0 (en) | 2014-03-31 |
JP2014521709A (ja) | 2014-08-28 |
EA023262B1 (ru) | 2016-05-31 |
CN103717589A (zh) | 2014-04-09 |
NZ620079A (en) | 2016-06-24 |
PE20142148A1 (es) | 2015-01-03 |
CL2014000311A1 (es) | 2014-10-17 |
CO6852080A2 (es) | 2014-01-30 |
ES2552016T3 (es) | 2015-11-25 |
CN103717589B (zh) | 2016-08-17 |
ECSP14013199A (es) | 2014-03-31 |
EA201490419A1 (ru) | 2014-05-30 |
HK1196131A1 (zh) | 2014-12-05 |
IL230458A (en) | 2015-11-30 |
KR20140045590A (ko) | 2014-04-16 |
US20130196974A1 (en) | 2013-08-01 |
CR20140026A (es) | 2014-05-12 |
USRE49481E1 (en) | 2023-04-04 |
MX349881B (es) | 2017-08-16 |
WO2013020993A1 (fr) | 2013-02-14 |
AU2012293644A1 (en) | 2014-01-30 |
KR101570627B1 (ko) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35432B1 (fr) | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
PH12017501429A1 (en) | Derivatives of betulin | |
EA201491283A1 (ru) | Ингибитор регулирующей апоптотические сигналы киназы | |
MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
IN2014MN02106A (fr) | ||
MY176210A (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
NZ708501A (en) | Treatment of pulmonary disease | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
IN2014CN04449A (fr) | ||
MX364400B (es) | Compuestos de tetraciclina. | |
IN2014DN05972A (fr) | ||
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
MX357763B (es) | Tratamiento para cancer pancreatico. | |
MX2013003202A (es) | Inhibidores de oxadiazol de la produccion de leucotrienos. | |
FR2961695B1 (fr) | Utilisation de composes dans le traitement ou la prevention de troubles cutanes | |
MX345264B (es) | Derivado de azol. | |
MA35010B1 (fr) | Inhibiteurs de la peptide déformylase | |
MX358470B (es) | Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus. | |
MA35534B1 (fr) | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial |